Best of ASCO - 2014 Annual Meeting

 

Welcome

Esophageal or Gastric Cancer

Gastrointestinal (Noncolorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multi-center, randomized, prospective study evaluating the optimal radiation dose of definitive concurrent chemoradiation for inoperable esophageal squamous cell carcinoma.

Yanjun Xu

4013

A phase II study of apatinib on reversing resistance of paclitaxel-containing regimens in advanced gastric cancer (AGC).

Rongbo Lin

e16055

A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.

Zhe Zhang

e16084

A phase II study of perioperative intraperitoneal paclitaxel plus S-1/paclitaxel for curatively resectable gastric cancer with serosal invasion: The GAPS study.

Seiji Ito

4033

A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.

Kensei Yamaguchi

TPS4133

A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).

Akitaka Makiyama

4011

A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).

Yasuhiro Kodera

4007

A retrospective study of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of gastric cancer with synchronous peritoneal metastasis.

Bin Xiong

e16007

A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909).

Yoshinori Ito

4051

Adjuvant radio chemotherapy for gastric cancer: Is chemotherapy alone better than combined radio chemotherapy? Results of a meta-analysis.

Jan Haussmann

e16030

Adjuvant treatment in stage III gastric cancer patients in Brazil and Peru: Results of a retrospective study in two cancer centers in Latin America.

Jose Eduardo Nunez

e16101

An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).

Daisuke Sakai

TPS4138

An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.

Tomohiro Nishina

TPS4131

Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction and gastric adenocarcinoma.

Ryosuke Okamura

e16031

Angiotensin system inhibitors during induction chemotherapy for esophageal adenocarcinoma: Analysis of survival.

Abraham Geller

e16066

Apatinib in patients with adenocarcinoma of stomach or gastroesophageal junction: A prospective, multicenter, non-interventional study (Ahead-G202).

Chunmei Bai

e16047

Apatinib plus SOX regimen as neoadjuvant chemotherapy for locally advanced gastric cancer: A phase II study.

Ya'nan Zheng

e16014

Association between Helicobacter pylori infection and outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.

Satoshi Nishizuka

4043

Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

Yasutaka Sukawa

4029

BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).

Yu-Xian Bai

e16027

Can chemoradiotherapy improve survival after an R1 resection for gastric cancer: A retrospective study of a Chinese cohort.

Menglong Zhou

e16092

Capecitabine plus oxaliplatin versus capecitabine plus oxaliplatin with concurrent radiotherapy in the treatment of gastric cancer after D2 gastrectomy.

Congying Xie

4059

Changes in bone metabolism after gastric cancer surgery: A prospective observational study.

Yosuke Atsumi

e16050

Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.

Janusz Jankowski

LBA4008

Circulating tumor DNA dynamics in resectable gastric cancer.

Alessandro Leal

4069

Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.

Shukui Qin

e16020

Clinical efficacy and safety of apatinib combined with docetaxel in second-line treatment for advanced gastric cancer: A prospective study.

Mudan Yang

e16006

Clinical impact of nodal status on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with gastric peritoneal metastasis.

Pierre Emmanuel Bonnot

e16093

Clinical-pathological features in HER2-positive advanced gastric cancer: Italian data of the Reggio Emilia Clinical Cancer Centre.

Francesco Iachetta

e16067

Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.

Joseph Chao

4063

Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.

Akina Natori

4066

Comparison of clinical outcome and safety after minimally invasive esophagectomy: Ivor Lewis versus McKeown—A real-world multicenter observational study from China.

Yang Liu

4052

Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC).

Luis Villanueva

e16016

Compliance with biweekly SOX combination chemotherapy versus triweekly SOX as a first-line therapy for elderly patients with advanced gastric cancer.

Shu Zhang

e16075

Comprehensive genomic profiling of gastric cancer to reveal distinctive genomic alterations between peritoneal metastasis (PM) patients (pts) and non-PM pts.

Rongbo Lin

e16063

Conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer: Updated data from a phase II trial.

Xiangdong Cheng

e16010

Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers.

Sassan Ostvar

e16089

Defective homologous recombination in platinum based chemotherapy for gastric cancer.

Hiroshi Ichikawa

e16068

Development of a prognostic index for gastric cancer with liver metastasis at the initial diagnosis: A single center retrospective study.

Yakun Wang

e16001

Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

Yi Ba

4039

Differential response to adjuvant chemotherapy based on Lauren subtype affects clinical outcome of gastric cancer: A cohort study and meta-analysis.

Kunning WANG

4048

Diversity of first-line palliative systemic treatments for esophagogastric cancer patients with synchronous metastases: A real world evidence study.

Willemieke P.M. Dijksterhuis

4064

Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.

Tienan Yi

e16022

Dynamic perspective of neutrophil-lymphocyte ratio in metastatic gastric cancer.

Antia Cousillas

e16095

Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.

Xiaoyan Lin

e16026

Effect of perioperative oral care on prevention of postoperative pneumonia associated with esophageal cancer surgery: A multicenter case-control study with propensity score matching analysis.

Sakiko Soutome

e16017

Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.

Kohei Shitara

4044

Efficacy and safety of apatinib with or without radiotherapy as second-line or beyond therapy in patients with advanced/recurrent esophageal squamous cell carcinoma.

Jiahua Lv

e16044

Efficacy and safety of chemotherapy DCX (DOCETAXEL–CISPLATIN–CAPECITABINE) as a perioperative treatment of gastric cancer: A single institution analysis.

Ismael Macias Declara

e16094

Enteral feeding during preoperative chemotherapy for patients with local advanced esophageal cancer: A feasibility study.

Takashi Ogata

e16012

Factors of local immunity in esophageal tumors of various stages.

Adlan Lechaevich Bazaev

e16013

Feasibility and clinical value of circulating tumor DNA testing in patients with gastroesophageal adenocarcinoma.

Madiha Iqbal

e16045

Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.

Sandor Schokker

4057

FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.

Daniel V.T. Catenacci

TPS4135

Final analysis of single-arm confirmatory study of diagnostic endoscopic resection(ER) plus selective chemoradiotherapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC): JCOG0508.

Keiko Minashi

4023

Final results of a phase 3 study of comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in chemoradiotherapy for locally advanced esophageal carcinoma (ESO-Shanghai 1).

Yun Chen

4053

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.

Sylvie Lorenzen

TPS4132

Fraction of diffuse gastric cancer attributable to dietary risk factors.

Marina Candido Visontai Cormedi

e16042

Frequency of overexpression of HER3 and prognostic consequences in European patients with early gastric cancer.

Nieves Martinez Lago

4068

Health-related quality-of-life (HRQoL) results from the FAST study, a phase 2 trial of epirubicin, oxaliplatin and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+ gastric (GA) and gastroesophageal junction (GEJ) adenocarcinoma.

Robert Morlock

e16005

Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.

Sonia Mansukhani

TPS4139

Immunomarker combined with clinical features to support vector machines classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefits.

Tuanjie Li

e16098

Impact of adjuvant FOLFOX on quality of life and peripheral neuropathy incidence in patients with localized gastric cancer.

Sebastián Mondaca

e16039

Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).

Zhong Xie

e16021

Incidence rate and clinic-pathologic features of EBV-associated gastric carcinoma in China.

Rui-hua Xu

e16048

Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.

Abraham Geller

4070

Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer.

Ronan Joseph Kelly

TPS4140

International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).

Masanori Terashima

4042

Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).

Karina Kulangara

4065

Is cytoreductive surgery and hyperthermic intraperitonealchemotherapy reasonable treatment for gastric signet-ring cell adenocarcinoma and linitis plastica with peritoneal metastasis? CYTO-CHIP study—Ancillary results.

Pierre Emmanuel Bonnot

4073

Is esophagectomy indicated after induction therapy in patients with clinical N3 esophageal cancer?

Shadia Ibrahim Jalal

e16073

KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.

Yung-Jue Bang

TPS4136

Laparoscopic sentinel node navigation surgery versus laparoscopic standard gastrectomy with lymph node dissection in early gastric cancer: Results of postoperative morbidity and mortality from a multicenter randomized controlled trial (SENORITA trial).

Keun Won Ryu

e16043

Laparoscopic versus open surgery for advanced gastric cancer.

Guoxin Li

4058

Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: Five year overall survival and morbidity results from a randomized phase II multicenter clinical trial (COACT 1001).

Young Woo Kim

4041

Long-term outcomes in laparoscopic D2 gastrectomy for gastric cancer: A large comprehensive study proposing novel hypotheses.

Tuanjie Li

e16025

Long-term prognosis of α-fetoprotein-producing gastric cancer defined as immunohistochemichal expression.

Yukio Maezawa

e16036

Lymph node ratio as a clinical determinant for selecting adjuvant chemotherapy regimen in curative D2 resected gastric cancer.

Jun-Eul Hwang

4034

Maintenance therapy with trastuzumab +/- fluoropyrimidine in non-progressive HER-2 positive advanced gastroesophageal cancer patients after first-line chemotherapy.

Anthony Lopez

e16071

Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Daniel V.T. Catenacci

4030

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

Do-Youn Oh

TPS4134

Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.

Tomomi Kashiwada

4038

Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.

Peter C. Enzinger

e16072

NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Michael Cecchini

TPS4137

Outcomes for advanced HER2 positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.

Charles Henry Lim

e16069

Oxaliplatin plus capecitabine (XELOX) in the perioperative treatment of locally advanced gastric adenocarcinoma in combination with D2 gastrectomy (NEO-CLASSIC).

Tianshu Liu

4022

Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).

Sarah Sophie Watson

4035

Paclitaxel combined with ramucirumab as the second-line chemotherapy for elderly patients with advanced gastric cancer.

Tetsuya Kusumoto

e16088

PD-L1 and IDO1 expression and clinical outcome in 305 patients with surgically resected esophageal cancer.

Yoshifumi Baba

4025

Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.

Charles S. Fuchs

4062

Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study.

Manish A. Shah

4049

Personal visceral fat index (PVF index), a new predictive factor for chemotherapy efficacy in patients with advanced gastric cancer.

Xiaodong Zhu

e16049

PET scan-directed chemoradiation (CRT) for esophageal squamous cell carcinoma (ESCC): No benefit for salvage chemo in PET non-responders (PETnr).

Megan Greally

4055

Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).

Yasuhide Yamada

4009

Phase III study of intraperitoneal/intravenous adjuvant chemotherapy compared intravenous adjuvant chemotherapy in patients with stage III gastric cancer.

Yang Yang

4067

Postradiation ctDNA status as a prognostic factor in locally advanced esophageal squamous cell carcinoma.

Ru Jia

e16053

Prediction of clinical outcomes for early gastric cancer using radiomic signatures derived from the quantitative texture analysis of conventional CT scans and machine learning.

Jacob G Woolsey

e16091

Preliminary result of phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma (NivoRam study).

Daisuke Takahari

4047

Prognostic factors associated with survival and recurrence in resectable gastric cancer: Retrospective analysis of 379 patients operated at Cremona Hospital from 2007 to 2016.

Michele Ghidini

e16079

Prognostic impact of PIK3CA mutation in esophageal cancer: Molecular profiling by next-generation sequencing using formalin-fixed, paraffin-embedded tissues.

Tomoya Yokota

e16003

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy.

Seok Yun Kang

e16008

Prognostic value of CEA mRNA in the peritoneal lavage of patients undergoing curative surgery for gastric cancer.

Yan Yang

e16090

Psychiatric comorbidities among esophageal cancer survivors in South Korea: A nationwide population-based, longitudinal study.

Jaesung Heo

4037

Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer.

Romy Van Amelsfoort

4060

Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer.

Dave Gupta

4027

Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).

Yoshiaki Iwasaki

4046

Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).

Kei Muro

4036

Real-world first-line advanced gastric cancer in western and Asian countries: Treatment patterns and impact on quality of life (QOL).

Sun Young Rha

e16018

Real-world outcomes and patient (pt) characteristics for the second-line (2L) treatment of gastric, esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (EGAC).

Afsaneh Barzi

e16011

Reconstruction of continuous isoperistaltic jejunum interposition after proximal gastrectomy preserving gastric antrum.

Xinbao Wang

e16046

Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).

Yifu He

e16028

Response to immune checkpoint inhibitors in recurrent/metastatic esophageal squamous cell carcinoma may be affected by tumor site and lesion size.

Jhe-Cyuan Guo

e16099

Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.

Se Hoon Park

e16029

Risk of second primary cancers among patients with stomach cancer: A population-based study in South Korea.

Jaesung Heo

e16054

Role of infiltrating CD8 lymphocytes, microsatellite instability and h. pylori level in gastric cancer.

Angela Leonardo

e16096

Role of neoadjuvant chemotherapy or chemoradiotherapy in oesophageal carcinoma.

Herui Yao

4040

Role of volume reduction gastrectomy according to tumor location in patients with gastric cancer with a single non-curable factor: Supplementary analysis of REGATTA trial (JCOG0705/KGCA01).

Kazumasa Fujitani

e16038

Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.

Antoine Hollebecque

4032

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Early results from Big Ten Cancer Research Consortium study.

Hirva Mamdani

e16070

Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

Ronan Joseph Kelly

4031

Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

Jin Li

e16019

Safety, antitumor activity and biomarker of anti-PD-1 antibody in patients with advanced esophageal carcinoma.

Xiangrui Meng

e16083

Safety, pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

Jifang Gong

e16059

Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.

Jeeyun Lee

4061

Should combination chemotherapy be used in all advanced gastric cancer patients?

Mi Sun Ahn

e16081

Single-arm confirmatory trial of laparoscopy assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401.

Hitoshi Katai

4028

Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

Karyn A. Goodman

4012

Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.

Sibo Tian

4026

Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma.

Jia Wei

e16065

Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.

Anthony Lopez

e16051

The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: Results from the AcSé-crizotinib program.

Thomas Aparicio

4054

The analysis of T cell subset and the expression of PD-L1, HLA in esophageal squamous cell carcinoma.

Tomoya Sudo

e16000

The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Manish A. Shah

4010

The correlation of CT volumetry with prognosis in advanced gastric cancer treated with neoadjuvant chemotherapy.

Chao Chen

e16061

The efficacy and safety of apatinib in the treatment of chemotherapy-resistant alpha-fetoprotein positive gastric cancer.

Feng Wang

e16080

The mutational landscape of circulating cell free DNA in patients with esophageal squamous cell carcinoma response and non-response to neoadjuvant chemotherapy.

Ruixiang Zhang

e16082

The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).

Satoshi Yuki

4050

Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.

Raghav Sundar

e16024

Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.

Itziar Gardeazabal

4071

Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.

Feng Wang

4045

Treatment decision priorities and decisional support experiences of gastric cancer survivors.

Linda S. House

e16037

Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).

Megan Greally

4056

Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.

Héctor van den Boorn

4021

Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.

Ronan Joseph Kelly

e16035

Updated report of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1).

Masanori Terashima

4024

What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).

Dung T. Le

e16023